KLRK1 and cancer: The simultaneous antibody targeting of both NKG2D ligands on cancer cells, in order to elicit an antitumor antibody-dependent cellular cytotoxicity (ADCC), and of the inhibitory receptor NKG2A on immune cells, highlighted an increased immune cell infiltration as well as a greater antitumor response (100).